Virus-virus Interactions Among Patients Admitted to the Hospices Civils de Lyon, During 2022 to 2025 Winters Seasons (INTERVI)

September 1, 2026 updated by: Hospices Civils de Lyon

Respiratory viruses circulate throughout the year, and particularly during the winter. Consequently, co-infections involving two or more viruses can occur. The study of virus-virus interactions at the population level is necessary to understand the dynamics of co-infections. Viruses such as IAV (influenza A virus) and rhinoviruses (common cold viruses) are known to have a negative interaction, mutually excluding one another, which results in a reduced likelihood of co-infection. The study of virus-virus interactions at the population level constitutes an essential first step towards understanding and characterising these phenomena at the individual level, and subsequently at the cellular level. Using integrative approaches combining epidemiological data, clinical observations and in vitro models, it has been shown that IAV and SARS-CoV-2 have a negative interaction, whilst potentially contributing to the severity of respiratory infections. This research also suggests that prior vaccination against IAV reduces the risk of severe forms of the disease.

Furthermore, viral co-infections appear to influence the severity of respiratory infections, particularly in children. Children appear to be more susceptible to these co-infections, with around 35% of cases reported, compared with 6% in adults. In this context, the study and characterisation of virus-virus interactions appear essential to better understand the pathophysiology of respiratory infections and improve the management of co-infected patients.

Every week, Dr Jean-Sébastien Casalegno publishes the Hospices Civils' epidemiological bulletin, which considers the prevalence of respiratory viruses detected at the Centre de Biologie et Pathologie Nord. This local dataset reports on the co-circulation of respiratory viruses and is of interest for the study of virus-virus interactions at a population level.

The impact of viral co-infections on the severity of respiratory infections remains a subject of debate in the literature. Understanding the dynamics of interaction between respiratory viruses at a population level, in order to identify preferential associations or exclusions, is essential for assessing the clinical impact of co-infections.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
114230

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Rhone
      • Lyon, Rhone, France, 69004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.

Description

Inclusion Criteria:

  • - Any virological result (positive or negative) following a biological sample taken as part of routine care within the HCLs for the purpose of diagnosing a respiratory infection in a hospitalised patient.
  • Patients of any age
  • Samples taken during the winter periods between 2022 and 2025.

Exclusion Criteria:

  • na

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Respiratory viral infections patients
Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.
Other: Virologic results
Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Virus-virus interactions over three consecutive winters
Time Frame: Baseline
To characterize virus-virus interactions from 2022 to 2025 by assessing a co-infection exclusion score in order to identify, based on PCR results from respiratory samples collected over specific time periods (months/years), the preferred (positive) associations and exclusion (negative) relationships between respiratory viruses.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Prevalence of confirmed co-infections
Time Frame: Baseline
Frequency of virologically confirmed co-infections, defined as the proportion of participants with a positive RT-PCR test for at least two respiratory viruses.
Baseline
Weekly circulation of respiratory viruses
Time Frame: Baseline
Description of the weekly circulation of respiratory viruses over the study period.
Baseline
Weekly prevalence of respiratory viruses
Time Frame: Baseline
Proportion of respiratory viruses detected among all samples taken during the study period, regardless of the PCR result.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 5, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 1, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 4, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 26-5170

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings